Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Study at a glance

From the registry record, last updated by the sponsor on 10 Sep 2012. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title

Observational Study on the Management of Patients With Non Small Cell Lung Cancer (NSCLC) Adenocarcinoma Tested for the Activating Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK)

ClinicalTrials.gov ID

NCT01167972

Acronym / sponsor ID

MUTACT / NIS-OFR-DUM-2010/1

Conditions

Non Small Cell Lung Cancer

Keywords

M + mutation, Non Small Cell Lung Cancer adenocarcinoma, To determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

Study type

Observational

Recruitment status

Completed

Enrolment

2,000 participants (actual)

Lead sponsor

AstraZenecaIndustry (pharma, biotech, devices)

Study start

Sep 2010

Primary completion

Sep 2012 (actual)

Study completion

Sep 2012 (actual)

First posted

22 Jul 2010 (estimated)

Results

Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model

Cohort

Time perspective

Prospective

Number of arms

1

Who may qualify

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Age groups

Adult, Older adult

Study population

Patient with NSCLC adenocarcinoma confirmed by histologyPatient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

1. The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

   Time frame: At baseline

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

• Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2012.

Related trials for Non Small Cell Lung Cancer

• RecruitingPhase 1/2

  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  Solid Tumor, Non-Small Cell Lung Cancer

• RecruitingObservational study

  A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC

  Non Small Cell Lung Cancer

• RecruitingPhase 3

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  Non-Small Cell Lung Cancer (NSCLC)

• Active, not recruitingPhase 2

  Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

  Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer

• Not yet recruitingPhase 1/2

  STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NSCLC, Non-Small Cell Lung Cancer

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

101 sites in 1 country: see every site and its status.